Sinopec First-Half Profit Rises 12%, Fuel Prices Lift

Sinopharm Group reported a roughly RMB 282.8 billion interim revenue for the six months ended June 30, 2026, a slight year‑on‑year decline, with net profit around RMB 5.18 billion and earnings per share of RMB 1.09, signaling mildly softer profitability among its pharmaceutical distribution operations. The results reflect tighter margins as cost of sales and operating expenses weighed on the topline. In Sinopec’s case, first‑half net profit rose about 19% year on year on stronger oil prices and higher upstream and high‑value product output, though second‑quarter profit fell as inventory gains waned, downstream weakness persisted, and refining stayed a drag. Analysts warned of a softer earnings outlook for the rest of 2026 amid expectations of moderating oil prices and slower domestic demand, with some forecasting only a gradual recovery in margins. Despite the mixed near‑term outlook, Sinopec’s dividend yield remains attractive at roughly 6%–7%, which could support the stock even as fundamentals become more cautious. A separate report also highlighted Sinopec’s six‑month net income rising about 12% to RMB 26.6 billion, underscoring energy‑price gains as a primary driver of H1 profitability.